Avalo Therapeutics (AVTX) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Avalo Therapeutics (AVTX) over the last 10 years, with Q3 2025 value amounting to -$2.19.
- Avalo Therapeutics' EPS (Weighted Average and Diluted) rose 2261.48% to -$2.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.64, marking a year-over-year increase of 9102.79%. This contributed to the annual value of -$20.91 for FY2024, which is 8159.01% up from last year.
- Per Avalo Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$2.19 for Q3 2025, which was up 2261.48% from -$1.92 recorded in Q2 2025.
- Avalo Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $117.47 for Q4 2023, and its period low was -$1059.6 during Q4 2022.
- For the 5-year period, Avalo Therapeutics' EPS (Weighted Average and Diluted) averaged around -$78.24, with its median value being -$2.12 (2021).
- Data for Avalo Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY increase of 11626.79% (in 2022) and a maximum YoY decrease of 5480207.25% (in 2022) over the last 5 years.
- Over the past 5 years, Avalo Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$1.93 in 2021, then tumbled by 54802.07% to -$1059.6 in 2022, then skyrocketed by 111.09% to $117.47 in 2023, then crashed by 98.54% to $1.72 in 2024, then plummeted by 227.33% to -$2.19 in 2025.
- Its last three reported values are -$2.19 in Q3 2025, -$1.92 for Q2 2025, and -$1.25 during Q1 2025.